SCRIBA NANOTECNOLOGIE SRL

Their core work

Scriba Nanotecnologie is a Bologna-based SME that develops nanotechnology-based biosensors and diagnostic devices, with particular strength in organic electronics applied to medical and food safety detection. They design and fabricate sensing platforms — including plasmonic, magnetic, and organic semiconductor-based devices — for applications ranging from early cancer detection to seafood quality monitoring. Their work sits at the intersection of materials science and applied diagnostics, translating lab-scale nanosensor research into functional prototypes and products like their temperature-monitoring tag system (T-TAG).

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), Scriba focused on fundamental organic electronics and plasmonic sensing materials, contributing to projects like iSwitch and ULTRAPLACAD that explored responsive materials and ultrasensitive diagnostic devices. From 2018 onward, their work shifted decisively toward applied biosensing — integrating organic semiconductors into diagnostic platforms for cancer (AiPBAND), neurodegenerative disease (MADIA), and food safety (ICHTHYS), while also incorporating digital tools like machine learning and cloud computing. This trajectory shows a clear maturation from materials research toward market-ready sensor products and broader application domains.

Scriba is expanding from medical diagnostics into food safety biosensing while adding digital/AI capabilities, suggesting they are positioning as a versatile sensor technology provider across regulated industries.

How they like to work

Scriba operates almost exclusively as a consortium partner (6 of 7 projects), contributing specialized nanosensor expertise to larger research teams rather than leading projects. Their single coordination role was a Phase 1 SME Instrument project (T-TAG), which is typical for SMEs testing commercial viability of their own product. With 81 unique partners across 17 countries, they are well-networked and comfortable integrating into diverse, multi-national consortia — a sign they are a reliable, low-friction partner for consortium builders.

Scriba has built a broad European network of 81 unique consortium partners spanning 17 countries, reflecting their participation in large MSCA training networks and multi-partner RIA projects. Their network is geographically diverse rather than concentrated in any single region.

What sets them apart

Scriba occupies an uncommon niche as an SME that bridges organic electronics fabrication and real-world biosensing applications — most companies in this space are either pure materials research labs or large diagnostic device manufacturers. Their ability to move between health diagnostics and food safety sensing using the same underlying organic semiconductor platform makes them a flexible partner for projects needing custom sensor development. The combination of nanotechnology fabrication capability with SME agility and strong MSCA training network involvement makes them particularly attractive for projects that need to train early-stage researchers while producing functional prototypes.

Highlights from their portfolio

• ULTRAPLACAD
  Largest single EC contribution (EUR 505,872 via iSwitch, but ULTRAPLACAD at EUR 270,250 targeted ultrasensitive plasmonic devices for early cancer diagnosis — directly tied to their diagnostic commercialization path).
• T-TAG
  Their only coordinated project — an SME Instrument Phase 1 feasibility study for a time-temperature monitoring tag, revealing their own product development ambitions beyond consortium research.
• AiPBAND
  Represents their most integrated effort combining biosensing, machine learning, cloud computing, and biomarker validation into a single brain cancer diagnostic platform.